Univariate and multivariate analyses of the clinicopathological factors with PFS and OS in the training set
| . | . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| Variable . | N (%) . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Univariate analysis | |||||||
| MYC IHC > 60% | 24 (11) | 2.31 | 1.02-5.24 | .0042* | 3.88 | 1.31-11.5 | <.0001* |
| MYC IHC ≤ 60% | 194 (89) | ||||||
| BCL2 IHC score 3+ | 89 (41) | 3.62 | 2.26-5.81 | <.0001* | 2.91 | 1.89-6.86 | <.0001* |
| BCL2 IHC score 0 to 2+ | 129 (59) | ||||||
| Non-GC type | 100 (46) | 1.56 | 0.99-2.44 | .048 | 1.57 | 0.94-2.67 | .08 |
| GC type | 118 (54) | ||||||
| MYC rearrangement+ | 30 (14) | 2.34 | 1.11-4.90 | .0016* | 2.99 | 1.29-6.93 | <.0001* |
| MYC rearrangement− | 188 (86) | ||||||
| BCL2 rearrangement+ | 20 (9) | 1.38 | 0.60-3.16 | .39 | 1.37 | 0.52-3.58 | .46 |
| BCL2 rearrangement− | 198 (91) | ||||||
| BCL6 rearrangement+ | 46 (21) | 1.09 | 0.64-1.87 | .74 | 1.07 | 0.57-2.01 | .82 |
| BCL6 rearrangement− | 172 (79) | ||||||
| IPI 3-5 | 61 (28) | 3.28 | 1.91-5.63 | <.0001* | 3.34 | 1.79-6.22 | <.0001* |
| IPI 0-2 | 157 (72) | ||||||
| Tumor size ≥7.5cm | 60 (28) | 1.73 | 1.02-2.92 | .019* | 1.77 | 0.96-3.26 | .0036* |
| Tumor size <7.5cm | 158 (72) | ||||||
| Multivariate analysis | |||||||
| IPI 3-5 | 3.36 | 2.11-5.37 | <.001 | 3.21 | 1.87-5.52 | <.001 | |
| Non-GC type | 1.55 | 0.78-2.15 | .32 | 1.58 | 0.87-2.86 | .13 | |
| BCL2 IHC score 3+ | 3.84 | 2.21-6.67 | <.001 | 2.13 | 1.21-3.75 | .009 | |
| MYC-deregulated | 2.32 | 1.28-4.19 | .005 | 3.66 | 1.92-6.98 | <.001 | |
| . | . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|---|
| Variable . | N (%) . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Univariate analysis | |||||||
| MYC IHC > 60% | 24 (11) | 2.31 | 1.02-5.24 | .0042* | 3.88 | 1.31-11.5 | <.0001* |
| MYC IHC ≤ 60% | 194 (89) | ||||||
| BCL2 IHC score 3+ | 89 (41) | 3.62 | 2.26-5.81 | <.0001* | 2.91 | 1.89-6.86 | <.0001* |
| BCL2 IHC score 0 to 2+ | 129 (59) | ||||||
| Non-GC type | 100 (46) | 1.56 | 0.99-2.44 | .048 | 1.57 | 0.94-2.67 | .08 |
| GC type | 118 (54) | ||||||
| MYC rearrangement+ | 30 (14) | 2.34 | 1.11-4.90 | .0016* | 2.99 | 1.29-6.93 | <.0001* |
| MYC rearrangement− | 188 (86) | ||||||
| BCL2 rearrangement+ | 20 (9) | 1.38 | 0.60-3.16 | .39 | 1.37 | 0.52-3.58 | .46 |
| BCL2 rearrangement− | 198 (91) | ||||||
| BCL6 rearrangement+ | 46 (21) | 1.09 | 0.64-1.87 | .74 | 1.07 | 0.57-2.01 | .82 |
| BCL6 rearrangement− | 172 (79) | ||||||
| IPI 3-5 | 61 (28) | 3.28 | 1.91-5.63 | <.0001* | 3.34 | 1.79-6.22 | <.0001* |
| IPI 0-2 | 157 (72) | ||||||
| Tumor size ≥7.5cm | 60 (28) | 1.73 | 1.02-2.92 | .019* | 1.77 | 0.96-3.26 | .0036* |
| Tumor size <7.5cm | 158 (72) | ||||||
| Multivariate analysis | |||||||
| IPI 3-5 | 3.36 | 2.11-5.37 | <.001 | 3.21 | 1.87-5.52 | <.001 | |
| Non-GC type | 1.55 | 0.78-2.15 | .32 | 1.58 | 0.87-2.86 | .13 | |
| BCL2 IHC score 3+ | 3.84 | 2.21-6.67 | <.001 | 2.13 | 1.21-3.75 | .009 | |
| MYC-deregulated | 2.32 | 1.28-4.19 | .005 | 3.66 | 1.92-6.98 | <.001 | |
CI, confidence interval; HR, hazard ratio; MYC-deregulated, cases with MYC IHC > 60% and/or MYC rearrangement/amplification positive.
P values significant after adjusted for multiple comparisons of PFS and OS using Bonferroni correction, α = 0.025.